Clinical trials: Insufficient Metabolic Control
Diabetes Mellitus, Type 2
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
- Trial name
- NCT00283049
- Testing
- Insulin Glargine, Insulin Glulisine
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Sanofi
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)
This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00289848
- Testing
- sitagliptin phosphate
- Volunteers
- 530 people
- Sponsor
- Merck Sharp & Dohme LLC
Gout
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an…
- Trial name
- NCT01399008
- Testing
- Arhalofenate, Allopurinol, Colchicine
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin.
- Trial name
- NCT02036515
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 464 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone.
- Trial name
- NCT01095666
- Testing
- Dapagliflozin, Metformin, Pioglitazone
- Where
- 33 sites in China, India and 1 more
- Volunteers
- 1,484 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1…
- Trial name
- NCT02500979
- Testing
- Pramlintide acetate, Lispro insulin U-100, Regular insulin U-100
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.
- Trial name
- NCT00543959
- Testing
- MK0533, Comparator: pioglitazone
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
- Trial name
- NCT01649297
- Testing
- empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid)
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 (10 mg, 25 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus…
- Trial name
- NCT01257334
- Testing
- BI 10773
- Where
- Taiwan
- Volunteers
- 1,390 people
- Sponsor
- Taipei Medical University WanFang Hospital
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately…
- Trial name
- NCT02681094
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 110 sites in United States, Canada and 4 more
- Volunteers
- 905 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24 weeks and 52 weeks in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT03159052
- Testing
- SHR3824
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 305 (NCT05504226)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Handok Inc.
Type 2 Diabetes
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.
- Trial name
- NCT01257412
- Testing
- Dapagliflozin
- Where
- 15 sites in India
- Volunteers
- 375 people
- Sponsor
- AstraZeneca
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
The purpose of this study is to assess the safety and efficacy of omarigliptin (MK-3102), dosed once-weekly in participants with T2DM who have inadequate glycemic control on diet and exercise.
- Trial name
- NCT01717313
- Testing
- Omarigliptin, Metformin, Glimepiride
- Volunteers
- 329 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
- Trial name
- NCT00819091
- Testing
- BI 1356
- Where
- 45 sites in United States, Argentina and 5 more
- Volunteers
- 245 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2…
- Trial name
- NCT02229396
- Testing
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Where
- 133 sites in United States, Hungary and 4 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes…
- Trial name
- NCT00601250
- Testing
- linagliptin
- Where
- 82 sites in United States, Czechia and 8 more
- Volunteers
- 701 people
- Sponsor
- Boehringer Ingelheim